Hanmi Pharm, Institutional Investors Net Sell 37,648 Shares Over Last 5 Days... Stock Price 360,500 KRW (-1.77%)

As of 9:30 AM on the 14th, Hanmi Pharm is trading at 360,500 KRW, down 1.77% from the previous day. The trading volume is 17,306 shares, which is about 18.66% of the previous day's volume. Hanmi Pharm is known as a pharmaceutical company specializing in the production of prescription drugs.

On January 13, Minjung Seon, a researcher at Hana Financial Investment, stated, "Among the new drugs developed by Hanmi Pharm in 2021, two are expected to receive approval from the US FDA. The PDUFA date for Oratoxel, developed by Athenex, remains February 28, and although the PDUFA date for Rolontis, which was postponed due to the COVID-19 pandemic, has not yet been rescheduled, if the inspection of the Pyeongtaek Bio New Plant, the manufacturing facility, is completed, approval within the year is highly anticipated. The R&D outlook for 2021 is promising." She set the target price for Hanmi Pharm at 410,000 KRW.

Over the past five days, individual investors have net purchased 21,025 shares of Hanmi Pharm, while foreign investors and institutions have net purchased 18,565 shares and net sold 37,648 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.